Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Mycosis Fungoides 2Neoplasms 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Amines × Clear all
NCT06149247 2025-08-20

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Soligenix

Phase 2 Completed
10 enrolled 7 charts
Lymphoid

Mycosis Fungoides

NCT02296164 2020-03-04

PROVe

Helsinn Therapeutics (U.S.), Inc

Completed
300 enrolled 7 charts
DermatologicLymphoid

Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡